Industry: Pharmaceuticals, Biotechnology
GTC Biotherapeutics develops, produces, and commercializes therapeutic proteins through transgenic animal technology. In August 2006, GTC obtained the first approval anywhere in the world of a therapeutic protein produced from a transgenic animal. ATryn®, GTC’s recombinant form of human antithrombin, was approved by the European Commission for use in patients with hereditary antithrombin deficiency undergoing surgical procedures. ATryn® is in phase III studies to support a filing in the United States requesting approval in the hereditary deficiency indication. LEO Pharma A/S of Denmark will launch ATryn® commercially in Europe and will work with GTC to develop ATryn® as a potential treatment for disseminated intravascular coagulation (DIC) in conjunction with severe ( www.gtc-bio.com )
GTC Biotherapeutics , Inc.
175 Crossing Blvd.
Framingham, Massachusetts 01702
USA
Tel: (508) 620-9700
Fax: (508) 370-3797